Cargando…
Understanding Drivers of Ocular Fibrosis: Current and Future Therapeutic Perspectives
Ocular fibrosis leads to severe visual impairment and blindness worldwide, being a major area of unmet need in ophthalmology and medicine. To date, the only available treatments are antimetabolite drugs that have significant potentially blinding side effects, such as tissue damage and infection. The...
Autores principales: | Mallone, Fabiana, Costi, Roberta, Marenco, Marco, Plateroti, Rocco, Minni, Antonio, Attanasio, Giuseppe, Artico, Marco, Lambiase, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584003/ https://www.ncbi.nlm.nih.gov/pubmed/34769176 http://dx.doi.org/10.3390/ijms222111748 |
Ejemplares similares
-
Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors
por: Mallone, Fabiana, et al.
Publicado: (2021) -
Autophagy-lysosome pathway alteration in ocular surface manifestations in Fabry disease patients
por: Marenco, Marco, et al.
Publicado: (2022) -
Hypoxia-dependent drivers of melanoma progression
por: D’Aguanno, Simona, et al.
Publicado: (2021) -
Understanding Vernal Keratoconjunctivitis: Beyond Allergic Mechanisms
por: Sacchetti, Marta, et al.
Publicado: (2021) -
Evidence of Pepsin-Related Ocular Surface Damage and Dry Eye (PROD Syndrome) in Patients with Laryngopharyngeal Reflux
por: Plateroti, Rocco, et al.
Publicado: (2020)